RPE65 — retinoid isomerohydrolase

The RPE65 gene provides the instructions for making a protein that is essential for normal vision. This protein works in a layer of cells at the back of the eye called the retinal pigment epithelium (RPE), which supports the light-sensing cells (photoreceptors) in the retina. The RPE65 protein acts like a recycling center; it helps convert the used form of vitamin A back into the active form that the eye needs to detect light. Without this active vitamin A, the eye cannot send visual signals to the brain. When a person has mutations (changes) in both copies of their RPE65 gene, this recycling process breaks down. As a result, the light-sensing cells cannot function properly and eventually die off. This leads to a group of inherited eye disorders, most commonly Leber congenital amaurosis (LCA) or severe early-onset retinitis pigmentosa (RP). Patients typically experience severe vision loss starting at birth or in early childhood, particularly struggling with night vision and side (peripheral) vision, which often progresses to legal blindness. These conditions are inherited in an autosomal recessive pattern, meaning a child must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry only one mutated copy are called carriers; they typically have normal vision but have a 25% chance of passing the condition to their children. Fortunately, RPE65-related vision loss is one of the few genetic eye diseases with an FDA-approved gene therapy (Luxturna), which can help restore some vision if treated early enough.

Gene description: Encodes a retinoid isomerohydrolase crucial for the visual cycle in the retinal pigment epithelium.

Patient and family guide: The RPE65 gene provides the instructions for making a protein that is essential for normal vision. This protein works in a layer of cells at the back of the eye called the retinal pigment epithelium (RPE), which supports the light-sensing cells (photoreceptors) in the retina. The RPE65 protein acts like a recycling center; it helps convert the used form of vitamin A back into the active form that the eye needs to detect light. Without this active vitamin A, the eye cannot send visual signals to the brain. When a person has mutations (changes) in both copies of their RPE65 gene, this recycling process breaks down. As a result, the light-sensing cells cannot function properly and eventually die off. This leads to a group of inherited eye disorders, most commonly Leber congenital amaurosis (LCA) or severe early-onset retinitis pigmentosa (RP). Patients typically experience severe vision loss starting at birth or in early childhood, particularly struggling with night vision and side (peripheral) vision, which often progresses to legal blindness. These conditions are inherited in an autosomal recessive pattern, meaning a child must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry only one mutated copy are called carriers; they typically have normal vision but have a 25% chance of passing the condition to their children. Fortunately, RPE65-related vision loss is one of the few genetic eye diseases with an FDA-approved gene therapy (Luxturna), which can help restore some vision if treated early enough.

Gene function: RPE65 is essential for vision, converting all-trans-retinyl esters to 11-cis-retinol in the retinal pigment epithelium. This step regenerates the chromophore for rhodopsin and cone opsins, enabling the eye to adapt to light and dark conditions and process visual signals.

Protein structure: The RPE65 gene encodes a 65-kilodalton (kDa) protein consisting of 533 amino acids. It belongs to the carotenoid cleavage dioxygenase (CCD) superfamily. The protein's structure features a seven-bladed beta-propeller fold, which is characteristic of this enzyme family. A critical feature of the RPE65 protein is its catalytic center, which contains an iron ion (Fe2+) coordinated by four highly conserved histidine residues. This iron center is essential for the enzyme's isomerohydrolase activity. The protein is highly hydrophobic and associates with the smooth endoplasmic reticulum membrane in the retinal pigment epithelium, a localization that is crucial for its access to its highly lipophilic substrates (retinyl esters).

Molecular function: The RPE65 gene encodes a 65-kDa protein known as retinoid isomerohydrolase, which is a critical enzyme in the visual cycle (retinoid cycle). The visual cycle is the biochemical pathway responsible for the continuous regeneration of 11-cis-retinal, the light-sensitive chromophore required by both rod and cone opsins for phototransduction. Specifically, RPE65 catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol within the retinal pigment epithelium (RPE). This 11-cis-retinol is subsequently oxidized to 11-cis-retinal, which is then transported back to the photoreceptors to recombine with opsin, forming functional visual pigments (rhodopsin in rods and cone opsins in cones). Without functional RPE65, the visual cycle is halted, leading to a severe deficiency of 11-cis-retinal, the accumulation of retinyl esters in the RPE, and the inability of photoreceptors to respond to light, ultimately resulting in retinal degeneration.

Expression pattern: The RPE65 gene is predominantly expressed in the retinal pigment epithelium (RPE), a single layer of cells located just outside the neurosensory retina. The RPE plays a critical role in nourishing and supporting the photoreceptor cells (rods and cones). Within the RPE, the RPE65 protein is localized to the smooth endoplasmic reticulum, where it functions as a key enzyme in the visual cycle. Its expression is highly specific to the RPE, although some studies have suggested low levels of expression in other tissues, its primary and most functionally significant location is the RPE. The expression of RPE65 is essential for the continuous regeneration of visual pigments required for sustained vision.

Mutation spectrum: The mutation spectrum of the RPE65 gene is diverse, encompassing over 200 known pathogenic variants. These include missense, nonsense, frameshift, and splice-site mutations, as well as small deletions and insertions. Missense mutations are the most common type, often affecting highly conserved amino acid residues critical for the enzyme's catalytic activity or structural stability. Mutations are distributed throughout the gene, with no single predominant hotspot, although certain variants may be more frequent in specific populations due to founder effects. The majority of pathogenic variants result in a loss of function, either by abolishing enzymatic activity, destabilizing the protein, or preventing its proper localization within the RPE cells.

Pathogenic variants: 1. p.Leu341Ser (c.1022T>C) - A common missense mutation, particularly prevalent in certain populations (e.g., Brazilian cohorts), associated with LCA and EOSRD. 2. p.Arg91Trp (c.271C>T) - A well-characterized hypomorphic missense mutation that often results in a milder phenotype, such as early-onset retinal dystrophy, due to residual enzymatic activity. 3. p.Tyr368His (c.1102T>C) - A frequently reported missense mutation associated with severe LCA phenotypes. 4. p.Glu417Gln (c.1249G>C) - Another common missense variant linked to autosomal recessive retinal degeneration. 5. c.11+5G>A - A splice-site mutation that disrupts normal mRNA splicing, leading to a loss of functional protein and severe disease.

Clinical significance: Mutations in the RPE65 gene are associated with a spectrum of autosomal recessive inherited retinal diseases (IRDs), primarily Leber congenital amaurosis (LCA) and early-onset severe retinal dystrophy (EOSRD), as well as some cases of retinitis pigmentosa (RP). LCA is the most severe phenotype, typically presenting at birth or within the first year of life with profound visual impairment, nystagmus, photophobia, and severely diminished or absent electroretinogram (ERG) responses. EOSRD is considered a slightly milder form, with onset between one and five years of age, characterized by some preservation of vision but still leading to severe visual loss. RPE65-associated RP generally presents later, in the first or second decade of life, with night blindness (nyctalopia) followed by progressive concentric visual field loss. Regardless of the specific diagnosis, RPE65 mutations consistently lead to progressive retinal degeneration, with patients often experiencing severe visual impairment or legal blindness by early adulthood. Systemic features are generally absent, as the disease is typically confined to the eye.

Inheritance: Autosomal Recessive

Chromosomal location: 1p31.3

Genotype-phenotype correlations: Genotype-phenotype correlations in RPE65-associated retinal dystrophies are complex and not always straightforward. Generally, the severity of the disease correlates with the residual enzymatic activity of the mutant RPE65 protein. Null mutations (e.g., nonsense, frameshift, or large deletions) that result in a complete loss of RPE65 function are typically associated with the more severe Leber congenital amaurosis (LCA) phenotype, characterized by profound visual loss from birth. Conversely, hypomorphic missense mutations that allow for some residual isomerohydrolase activity may result in milder phenotypes, such as early-onset severe retinal dystrophy (EOSRD) or juvenile retinitis pigmentosa (RP). However, significant phenotypic variability can exist even among individuals with the same mutations, suggesting that other genetic or environmental modifiers may influence disease expression and progression.

Research and therapeutic approaches: The most significant therapeutic advancement for RPE65-associated retinal dystrophy is the development of voretigene neparvovec-rzyl (Luxturna), an FDA-approved gene therapy. Luxturna uses a recombinant adeno-associated virus (AAV2) vector to deliver a functional copy of the human RPE65 gene directly to the retinal pigment epithelium cells via subretinal injection. This therapy has been shown to significantly improve visual function, particularly light sensitivity and navigational ability in low-light conditions, in patients with viable retinal cells. In addition to gene therapy, oral retinoid supplementation has been investigated as a pharmacological approach to bypass the enzymatic defect. Clinical trials have explored the use of synthetic 9-cis-retinyl acetate (e.g., QLT091001), which can substitute for the missing 11-cis-retinal and bind to opsins to form functional visual pigments. While early phase trials showed some improvements in visual fields and acuity, this approach requires ongoing treatment and does not correct the underlying genetic defect. Other pipeline strategies may include novel gene delivery vectors or gene editing technologies like CRISPR/Cas9, though these are still in preclinical or early clinical stages.

Diagnostic testing: Diagnosis of RPE65-associated retinal dystrophy involves a combination of clinical evaluation and genetic testing. Clinical assessments typically include best-corrected visual acuity (BCVA), visual field testing, optical coherence tomography (OCT) to evaluate retinal structure, fundus autofluorescence (FAF), and full-field electroretinography (ERG) to assess photoreceptor function. Definitive diagnosis requires molecular genetic testing, usually performed via multi-gene panels for inherited retinal diseases or whole exome/genome sequencing. Identifying biallelic pathogenic variants in RPE65 is crucial not only for confirming the diagnosis but also for determining eligibility for targeted gene therapy (Luxturna). Genetic counseling is highly recommended to inform patients and families about the autosomal recessive inheritance pattern, the risk to future offspring, and the implications for family members.

Animal models: Animal models have been instrumental in understanding RPE65 function and developing therapies. The Rpe65 knockout mouse model (Rpe65-/-) exhibits early and severe visual impairment, mimicking human Leber congenital amaurosis (LCA). These mice fail to produce 11-cis-retinal, leading to an accumulation of retinyl esters in the RPE and rapid degeneration of photoreceptors. Studies in these mice provided the first proof-of-concept for gene therapy and oral retinoid supplementation. The naturally occurring Briard dog model, which carries a null mutation in the RPE65 gene, has been particularly crucial for translational research. These dogs are congenitally night blind and have severe visual deficits in daylight. The successful restoration of vision in these dogs using adeno-associated virus (AAV) vector-mediated gene therapy paved the way for human clinical trials, ultimately leading to the FDA approval of voretigene neparvovec-rzyl (Luxturna).

Population genetics: RPE65 mutations are a relatively rare cause of inherited retinal diseases overall, accounting for approximately 1-2% of all retinitis pigmentosa cases and up to 16% of Leber congenital amaurosis cases. The carrier frequency in the general population is estimated to be low, though specific rates can vary by ethnicity. Certain mutations may exhibit founder effects in isolated or consanguineous populations, leading to a higher local prevalence of the disease. For example, specific variants have been noted to be more common in certain European or South American cohorts.

Selected references: 1. Maguire AM, et al. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy. Mol Ther. 2021. PMID: 33453155 2. Chung DC, et al. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene. Am J Ophthalmol. 2019. PMID: 30243663 3. Russell S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017. PMID: 28712537 4. Morimura H, et al. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc Natl Acad Sci U S A. 1998. PMID: 9501220 5. Redmond TM, et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet. 1998. PMID: 9843205 6. Cenachi SPF, et al. Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration: A study from a tertiary eye care center in Brazil. Mol Vis. 2025. PMID: 40384766